BioNTech Investor Day Presentation Deck slide image

BioNTech Investor Day Presentation Deck

BNT151 mediates CAR T cell expansion in non-tumor bearing mice # CAR Ts = Total flus [p/s] 108 107 Data on file. Tuto Comparable in vivo expansion of CAR T cells in CLDN6-LPX or BNT151 treated mice 5 Days post ACT 10 CAR T dose 2x106 2x106 2x106 2x107 Treatment + CLDN6-LPX + BNT 151 + CLDN6-LPX + BNT151 + ctrl-LPX + crtl-LNP Treatment Time point of analysis Day 1 (Baseline) 1° treatment - Day 1 Day 4 Day 7 2° treatment Day 7 Day 9 Day 10 CLDN6-CAR-BBz-Luc-GFP positive T cells 2x106 2x107 CLDN6-LPX CLDN6-LPX BNT151 BNT 151 NUM C6-LPX+ BNT151 Ctr-LPX + ctrl-LNP C6-LPX+ BNT151 Ctr-LPX + ctrl-LNP Splenocytes isolated for ex vivo cytotox assay BNT151 treatment leads to initial similar CAR T cell expansion in vivo compared to CLDN6-LPX treatment BNT151-mediated CAR T expansion peaks at day 3/4 after treatment, followed by contraction phase at day 7 CLDN6-LPX + BNT151 improves CAR T cell expansion RiboCytokines 10.0 8.0 6.0 x105 4.0 2.0 Radiance (p/sec/cm²/sr) Color Scale Min = 2.00e5 Max 1.00e6 BIONTECH 149
View entire presentation